ATRC Treats First Patients Using Novel Dual-Energy PFA-RFA Platform

AtriCure's first patients treated with its dual-energy PFA-RFA platform mark a key step as it moves toward a clinical trial next year.

Zacks Investment Research • Dec 12, 2025

AtriCure Announces the First Patients Treated with Novel Dual Energy Platform

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced successful first-in-human treatments using its novel dual energy platform that integrates Pulsed Field Ablation (PFA) with Advanced Radiofrequency Ablation (Advanced RFA). The procedures were performed by Dr. Adrian Pick in collaboration with the site Princi.

Business Wire • Dec 11, 2025

Are Medical Stocks Lagging AtriCure (ATRC) This Year?

Here is how AtriCure (ATRC) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Zacks Investment Research • Dec 8, 2025

Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?

AtriCure Board of Directors member Sven Wehrwein sold 10,000 shares in the company on Nov. 24 and 25, 2025. The transaction was valued at nearly $377,000.

The Motley Fool • Nov 29, 2025

Wall Street Analysts Believe AtriCure (ATRC) Could Rally 36.3%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in AtriCure (ATRC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Nov 25, 2025

Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?

Here is how AtriCure (ATRC) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.

Zacks Investment Research • Nov 20, 2025

AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 37th Annual Healthcare Conference. AtriCure's management is scheduled to participate in a fireside discussion on Tuesday, December 2, 2025, at 10:00 a.m. Eastern Standard Time. Interested.

Business Wire • Nov 18, 2025

AtriCure, Inc. (ATRC) Presents at UBS Global Healthcare Conference 2025 Transcript

AtriCure, Inc. ( ATRC ) UBS Global Healthcare Conference 2025 November 10, 2025 2:00 PM EST Company Participants Angela Wirick - Chief Financial Officer Michael H. Carrel - CEO, President & Director Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division Well, good afternoon, everyone.

Seeking Alpha • Nov 10, 2025

AtriCure (ATRC) Loses 13.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for AtriCure (ATRC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Investment Research • Nov 7, 2025

Here's What Key Metrics Tell Us About AtriCure (ATRC) Q3 Earnings (Revised)

While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Nov 6, 2025